This class of biologic may work particularly well in blood cancers with mutated nucleophosmin 1 (NPM1). The antibody may be combined with a delta opioid receptor (DOR) inhibitor and/or a menin ...

It comes a few days after the company's shares came under pressure from the results of a phase 1/2 trial of Revuforj in relapsed or refractory mutant NPM1 acute myeloid leukaemia (AML), a follow ...

The company recently announced that its pivotal Phase 2 KOMET-001 trial in relapsed/refractory NPM1-mutated AML met its primary endpoint. Detailed results are expected to be presented at a medical ...

Kura Oncology (KURA) and Kyowa Kirin announced topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly ...

We look forward to sharing topline data at an upcoming medical conference and expect to submit a New Drug Application (NDA) in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML ...